Clients using Semaglutide GLP-1 for weight management have achieved substantial, sustained reductions in body weight over time
However, native GLP-1 has a short half-life of approximately 23 min, limiting its therapeutic potential [12]
(semaglutide)(cagrilintide)(NovoPen 4 penfill) 7 AM833 ( (cagrilintide)) (semaglutide) 1 These non-clinical data may indicate that when a dual-chamber device is used to administer semaglutide and cagrilintide in a single injection, an enhanced effect is obtained
Dual and Triple Agonists Tirzepatide (Mounjaro/Zepbound) Tirzepatide is the first true dual or co-agonist, activating both GLP-1 and GIP receptors, a pairing often called a twincretin
Ogawa et al., 2025)), cancer history, or significant cardiovascular disease
Abstract The development of glucagon-like peptide 1 (GLP1) receptor agonists, including semaglutide and tirzepatide, has transformed the clinical management of overweight and obesity